argenx SE
OTC: ARGNF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Timothy Van Hauwermeiren
- Employees
- 1,599
- Headquarters
- Breda, Netherlands
- IPO year
- 2015
- Market cap
- $55.7B
- Website
- https://www.argenx.com
Loading ARGNF…
Loading profile data…Frequently asked questions about ARGNF
What does argenx SE (ARGNF) do?
argenx SE operates as a biotechnology firm, specializing in the advancement of various therapeutic solutions for autoimmune diseases across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's flagship investigational therapy is efgartigimod, currently undergoing Phase III clinical trials for condit...
Where does ARGNF trade?
argenx SE (ARGNF) trades on the Other OTC.
What sector is ARGNF in?
argenx SE (ARGNF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of argenx SE?
Timothy Van Hauwermeiren is the chief executive officer of argenx SE (ARGNF).
Where is argenx SE headquartered?
argenx SE is headquartered in Netherlands.
Does ARGNF pay a dividend?
argenx SE (ARGNF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ARGNF go public?
argenx SE (ARGNF) completed its initial public offering in 2015.